OClawVPS.com
Codiak BioSciences
Edit

Codiak BioSciences

http://www.codiakbio.com/
Last activity: 04.04.2025
Active
Categories: BioTechDesignDevelopmentMedTechPlatform
About Codiak BioSciences

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Followers
312
Followers
7.75K
Mentions
30
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $300M
Founded date: 2015
Twitter
Facebook
LinkedIn
Email

Investors 2

Funding Rounds 4

DateSeriesAmountInvestors
14.10.2020IPO$82M-
29.11.2017Series C$77M-
26.01.2016Series B$61M-
18.11.2015Series A$80M-

Mentions in press and media 30

DateTitleDescription
06.04.2025Pillar VC's New Fund: A Catalyst for Scientific InnovationPillar VC has struck gold with its latest venture, closing a $175 million Fund IV. This move elevates the firm’s total assets under management to over $500 million. It’s a bold step into the future, one that promises to bridge the gap betwe...
04.04.2025Pillar VC: $175 Million Fund IV ClosedPillar VC recently announced its $175 million Fund IV, bringing the firm’s total assets under management to more than $500 million. And Pillar VC is also introducing three new Venture Partners, and four new Founding Pillars, a group of CEOs...
13.09.2022Two biotechs go for pub­lic of­fer­ings; Pfiz­er part­ner ex­pands on­col­o­gy col­labAf­ter the FDA ap­proved Re­vance’s Daxxi­fy as a longer-last­ing al­ter­na­tive to Ab­b­Vie’s cash cow Botox, Re­vance is look­ing to top off its cof­fers. The aes­thet­ics com­pa­ny is of­fer­ing 8 mil­lion shares of its com­mon stock, pr...
13.09.2022Codiak Announces Pricing of $20 Million Public Offering of Common Stock and WarrantsCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. CDAK ("Codiak"), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announ...
04.11.2021Al­pha­bet kick­starts new AI drug dis­cov­ery out­fit with lessons learned from Deep­Mind pro­tein break­throughsModerna’s stock $MRNA plunged more than 14% in premarket trading on Thursday after the biotech cut its end-of-year vaccine sales forecast. According to its Q3 results, Moderna now plans on delivering between 700 million and 800 million dose...
04.11.2021Blue­bird bio com­pletes split in­to two com­pa­nies; BeiGene builds out Brukin­sa da­ta at ASHBlue­bird bio has been of­fi­cial­ly split in half. Both sides of the once-sin­gu­lar cell and gene ther­a­py com­pa­ny an­nounced Thurs­day they have com­plet­ed their split in­to two biotechs: A gene ther­a­py-fo­cused out­fit that will r...
04.11.2021Lon­za en­ters the ex­o­some ther­a­py space with ac­qui­si­tion of still-new Co­di­ak siteIn an­tic­i­pa­tion of tack­ling the man­u­fac­tur­ing prob­lems that come with ex­o­some ther­a­peu­tics head on, Co­di­ak Bio­Sciences built a 12,000-square-foot man­u­fac­tur­ing site in Lex­ing­ton, MA. Tues­day, it an­nounced that it w...
04.11.2021Platelet­Bio an­nounces $75.5M Se­ries B to ex­tend au­toim­mune cell ther­a­pyMore than two years af­ter Platelet­Bio land­ed its first round of fundrais­ing and a con­tract with the US gov­ern­ment, the com­pa­ny an­nounced its Se­ries B round Thurs­day. The pre­clin­i­cal stage biotech out of Wa­ter­town, MA an­nou...
04.11.2021More than a year af­ter trim­ming R&D unit, Iron­wood adds a rare dis­ease drug to the pipeline in hope­ful step for­wardIron­wood Phar­ma­ceu­ti­cals has walked a less-than-easy path the past few years with a proxy-dri­ven shake­up and mul­ti­ple clin­i­cal fail­ures rock­ing the com­pa­ny. Now un­der new lead­er­ship, Iron­wood is snag­ging rights to a rare...
04.11.2021Al­pha­bet kick­starts new AI drug dis­cov­ery out­fit with lessons learned from Deep­Mind pro­tein break­throughsLast sum­mer marked a ma­jor break­through in drug dis­cov­ery when Deep­Mind, a pre­dic­tive mod­el­ing start­up from Google par­ent com­pa­ny Al­pha­bet, of­fered the most ac­cu­rate pic­ture yet of the “pro­tein fold­ing” prob­lem. The A...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In